Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
6
SLS Quote, Financials, Valuation and Earnings
Last price:
$0.90
Seasonality move
:
2.47%
Day range:
$0.87 - $0.93
52-week range:
$0.50 - $1.72
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.99x
Volume:
1.1M
Avg. volume:
1.5M
1-year change:
-26.18%
Market cap:
$63.4M
Revenue:
--
EPS (TTM):
-$0.69
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group
|
-- | -$0.13 | -- | -57.33% | -- |
|
AVXL
Anavex Life Sciences
|
-- | -$0.17 | -- | -30.77% | -- |
|
GALT
Galectin Therapeutics
|
-- | -- | -- | -- | -- |
|
MBOT
Microbot Medical
|
-- | -$0.17 | -- | -32% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | -- |
|
TCRT
Alaunos Therapeutics
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group
|
$0.90 | -- | $63.4M | -- | $0.00 | 0% | -- |
|
AVXL
Anavex Life Sciences
|
$8.63 | -- | $731.8M | -- | $0.00 | 0% | -- |
|
GALT
Galectin Therapeutics
|
$1.03 | -- | $64.6M | -- | $0.00 | 0% | -- |
|
MBOT
Microbot Medical
|
$0.97 | -- | $16.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$0.36 | -- | $4.3M | -- | $0.00 | 0% | 1.40x |
|
TCRT
Alaunos Therapeutics
|
$2.03 | -- | $3.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group
|
-- | 0.853 | -- | -- |
|
AVXL
Anavex Life Sciences
|
-- | 3.153 | -- | -- |
|
GALT
Galectin Therapeutics
|
-- | -3.116 | -- | -- |
|
MBOT
Microbot Medical
|
-- | 2.795 | -- | -- |
|
OGEN
Oragenics
|
-- | 5.927 | -- | -- |
|
TCRT
Alaunos Therapeutics
|
-- | 2.640 | -- | 2.72x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group
|
-- | -$7.3M | -- | -- | -- | -$7.8M |
|
AVXL
Anavex Life Sciences
|
-- | -$14.7M | -- | -- | -- | -$5.2M |
|
GALT
Galectin Therapeutics
|
-- | -$9.1M | -- | -- | -- | -$8.5M |
|
MBOT
Microbot Medical
|
-- | -$3.3M | -- | -- | -- | -$2.8M |
|
OGEN
Oragenics
|
-- | -$2.4M | -- | -- | -- | -$2M |
|
TCRT
Alaunos Therapeutics
|
-- | -$1.2M | -189.69% | -189.69% | -28225% | -$781K |
SELLAS Life Sciences Group vs. Competitors
-
Which has Higher Returns SLS or AVXL?
Anavex Life Sciences has a net margin of -- compared to SELLAS Life Sciences Group's net margin of --. SELLAS Life Sciences Group's return on equity of -- beat Anavex Life Sciences's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group-- -$0.10 -- AVXLAnavex Life Sciences-- -$0.14 -- -
What do Analysts Say About SLS or AVXL?
SELLAS Life Sciences Group has a consensus price target of --, signalling upside risk potential of 547.72%. On the other hand Anavex Life Sciences has an analysts' consensus of -- which suggests that it could grow by 311.04%. Given that SELLAS Life Sciences Group has higher upside potential than Anavex Life Sciences, analysts believe SELLAS Life Sciences Group is more attractive than Anavex Life Sciences.
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group0 0 0 AVXLAnavex Life Sciences0 0 0 -
Is SLS or AVXL More Risky?
SELLAS Life Sciences Group has a beta of 2.391, which suggesting that the stock is 139.11% more volatile than S&P 500. In comparison Anavex Life Sciences has a beta of 0.729, suggesting its less volatile than the S&P 500 by 27.09%.
-
Which is a Better Dividend Stock SLS or AVXL?
SELLAS Life Sciences Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group pays -- of its earnings as a dividend. Anavex Life Sciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or AVXL?
SELLAS Life Sciences Group quarterly revenues are --, which are smaller than Anavex Life Sciences quarterly revenues of --. SELLAS Life Sciences Group's net income of -$7.1M is higher than Anavex Life Sciences's net income of -$12.2M. Notably, SELLAS Life Sciences Group's price-to-earnings ratio is -- while Anavex Life Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group is -- versus -- for Anavex Life Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group-- -- -- -$7.1M AVXLAnavex Life Sciences-- -- -- -$12.2M
-
Which has Higher Returns SLS or GALT?
Galectin Therapeutics has a net margin of -- compared to SELLAS Life Sciences Group's net margin of --. SELLAS Life Sciences Group's return on equity of -- beat Galectin Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group-- -$0.10 -- GALTGalectin Therapeutics-- -$0.18 -- -
What do Analysts Say About SLS or GALT?
SELLAS Life Sciences Group has a consensus price target of --, signalling upside risk potential of 547.72%. On the other hand Galectin Therapeutics has an analysts' consensus of -- which suggests that it could grow by 967.96%. Given that Galectin Therapeutics has higher upside potential than SELLAS Life Sciences Group, analysts believe Galectin Therapeutics is more attractive than SELLAS Life Sciences Group.
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group0 0 0 GALTGalectin Therapeutics0 0 0 -
Is SLS or GALT More Risky?
SELLAS Life Sciences Group has a beta of 2.391, which suggesting that the stock is 139.11% more volatile than S&P 500. In comparison Galectin Therapeutics has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.07%.
-
Which is a Better Dividend Stock SLS or GALT?
SELLAS Life Sciences Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galectin Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group pays -- of its earnings as a dividend. Galectin Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or GALT?
SELLAS Life Sciences Group quarterly revenues are --, which are smaller than Galectin Therapeutics quarterly revenues of --. SELLAS Life Sciences Group's net income of -$7.1M is higher than Galectin Therapeutics's net income of -$11.2M. Notably, SELLAS Life Sciences Group's price-to-earnings ratio is -- while Galectin Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group is -- versus -- for Galectin Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group-- -- -- -$7.1M GALTGalectin Therapeutics-- -- -- -$11.2M
-
Which has Higher Returns SLS or MBOT?
Microbot Medical has a net margin of -- compared to SELLAS Life Sciences Group's net margin of --. SELLAS Life Sciences Group's return on equity of -- beat Microbot Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group-- -$0.10 -- MBOTMicrobot Medical-- -$0.20 -- -
What do Analysts Say About SLS or MBOT?
SELLAS Life Sciences Group has a consensus price target of --, signalling upside risk potential of 547.72%. On the other hand Microbot Medical has an analysts' consensus of -- which suggests that it could grow by 618.32%. Given that Microbot Medical has higher upside potential than SELLAS Life Sciences Group, analysts believe Microbot Medical is more attractive than SELLAS Life Sciences Group.
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group0 0 0 MBOTMicrobot Medical0 0 0 -
Is SLS or MBOT More Risky?
SELLAS Life Sciences Group has a beta of 2.391, which suggesting that the stock is 139.11% more volatile than S&P 500. In comparison Microbot Medical has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.938%.
-
Which is a Better Dividend Stock SLS or MBOT?
SELLAS Life Sciences Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Microbot Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group pays -- of its earnings as a dividend. Microbot Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or MBOT?
SELLAS Life Sciences Group quarterly revenues are --, which are smaller than Microbot Medical quarterly revenues of --. SELLAS Life Sciences Group's net income of -$7.1M is lower than Microbot Medical's net income of -$3.2M. Notably, SELLAS Life Sciences Group's price-to-earnings ratio is -- while Microbot Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group is -- versus -- for Microbot Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group-- -- -- -$7.1M MBOTMicrobot Medical-- -- -- -$3.2M
-
Which has Higher Returns SLS or OGEN?
Oragenics has a net margin of -- compared to SELLAS Life Sciences Group's net margin of --. SELLAS Life Sciences Group's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group-- -$0.10 -- OGENOragenics-- -$0.38 -- -
What do Analysts Say About SLS or OGEN?
SELLAS Life Sciences Group has a consensus price target of --, signalling upside risk potential of 547.72%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 25237.83%. Given that Oragenics has higher upside potential than SELLAS Life Sciences Group, analysts believe Oragenics is more attractive than SELLAS Life Sciences Group.
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group0 0 0 OGENOragenics0 0 0 -
Is SLS or OGEN More Risky?
SELLAS Life Sciences Group has a beta of 2.391, which suggesting that the stock is 139.11% more volatile than S&P 500. In comparison Oragenics has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.551%.
-
Which is a Better Dividend Stock SLS or OGEN?
SELLAS Life Sciences Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or OGEN?
SELLAS Life Sciences Group quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. SELLAS Life Sciences Group's net income of -$7.1M is lower than Oragenics's net income of -$2.5M. Notably, SELLAS Life Sciences Group's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group is -- versus 1.40x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group-- -- -- -$7.1M OGENOragenics1.40x -- -- -$2.5M
-
Which has Higher Returns SLS or TCRT?
Alaunos Therapeutics has a net margin of -- compared to SELLAS Life Sciences Group's net margin of -28225%. SELLAS Life Sciences Group's return on equity of -- beat Alaunos Therapeutics's return on equity of -189.69%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group-- -$0.10 -- TCRTAlaunos Therapeutics-- -$0.70 $3.8M -
What do Analysts Say About SLS or TCRT?
SELLAS Life Sciences Group has a consensus price target of --, signalling upside risk potential of 547.72%. On the other hand Alaunos Therapeutics has an analysts' consensus of -- which suggests that it could grow by 10027.64%. Given that Alaunos Therapeutics has higher upside potential than SELLAS Life Sciences Group, analysts believe Alaunos Therapeutics is more attractive than SELLAS Life Sciences Group.
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group0 0 0 TCRTAlaunos Therapeutics0 0 0 -
Is SLS or TCRT More Risky?
SELLAS Life Sciences Group has a beta of 2.391, which suggesting that the stock is 139.11% more volatile than S&P 500. In comparison Alaunos Therapeutics has a beta of -0.444, suggesting its less volatile than the S&P 500 by 144.433%.
-
Which is a Better Dividend Stock SLS or TCRT?
SELLAS Life Sciences Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alaunos Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group pays -- of its earnings as a dividend. Alaunos Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or TCRT?
SELLAS Life Sciences Group quarterly revenues are --, which are smaller than Alaunos Therapeutics quarterly revenues of $4K. SELLAS Life Sciences Group's net income of -$7.1M is lower than Alaunos Therapeutics's net income of -$1.1M. Notably, SELLAS Life Sciences Group's price-to-earnings ratio is -- while Alaunos Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group is -- versus -- for Alaunos Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group-- -- -- -$7.1M TCRTAlaunos Therapeutics-- -- $4K -$1.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
